FindTrial
Sign In

Novel Anti Thirst Drug

EVALUATION OF AMALAKYADI GUTIKA AS A NOVEL ANTI THIRST DRUG

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/01/022830
Enrollment
120
Registered
2020-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: AMALAKYADI GUTIKA: GUTIKA, DOSAGE- 500mg BD with water Intervention2: AMALAKYADI GUTIKA with Water Ad libitum: GUTIKA, DOSAGE-500mg with Water Ad libitum daily for 15 days Control Inter

Sponsors

PARUL INSTITUE OF AYURVED
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Apparently healthy volunteers

Exclusion criteria

Exclusion criteria: 1.Subject who do not fulfill the inclusion criteria will be excluded from the study. 2. Pregnant and lactating women will be excluded. 3.Subject having uncontrolled DM/HTN/Hypo Or Hyperthyroidism/Nephrotic Syndrome/Epileptic Syndrome and other systemic disorder will be excluded.

Design outcomes

Primary

MeasureTime frame
AMALAKYADI GUTIKA is a noval anti thirst drug and it will be assessed by dehydration assessment scale.Timepoint: 15 days—

Secondary

MeasureTime frame
AMALAKYADI GUTIKA is not working on thirstTimepoint: 15 days—

Countries

India

Contacts

Public ContactDr Raghuveer

Parul Institute of Ayurved

drraghuveer07@gmail.com9945872608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026